Navigation Links
Mayo Clinic Identifies Best Treatments for Long-Term Survival in Brain Tumor Patients
Date:12/3/2008

Patients who had aggressive surgeries were free of tumor recurrence an average of 15 years after diagnosis

ROCHESTER, Minn., Dec. 3 /PRNewswire-USNewswire/ -- A new Mayo Clinic study found that patients with low-grade gliomas survived longest when they underwent aggressive surgeries to successfully remove the entire tumor. If safely removing the entire tumor was not possible, patients survived significantly longer when surgery was followed by radiation therapy. This study is available online as an advance publication in Neuro-Oncology.

VIDEO ALERT: Additional audio and video resources, including excerpts from an interview with Dr. Laack describing the research, are available on the Mayo Clinic News Blog (http://newsblog.mayoclinic.org/about/).

Gliomas are a type of brain tumor that form in the brain or spinal cord tissue and can spread within the nervous system. Low-grade gliomas are malignant and slow growing; overall, patients' average survival is five to seven years after diagnosis, even with treatment. Annually, about 17,000 Americans are diagnosed with a glioma. Of that total, 3,000 to 4,000 are categorized as low-grade. Mayo Clinic physicians treat more than 4,000 adults and children who have gliomas and other brain and nervous system tumors each year.

"Mayo Clinic has a long history of expertise in treating patients with brain tumors," says Nadia Laack, M.D., a Mayo Clinic radiation oncologist and lead author of this study. "This makes our study unique in terms of the large volumes of patients seen here and the extensive length of follow-up."

Dr. Laack and a team of Mayo Clinic researchers studied the records of 314 adult patients with low-grade gliomas who were di
'/>"/>

SOURCE Mayo Clinic
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
2. Radiologists encouraged to look beyond cancer for clinically unseen diseases
3. Clinical depression linked to abnormal emotional brain circuits
4. Preclinical study suggests organ-transplant drug may aid in lupus fight
5. Mayo Clinic researchers discover new diagnostic test for detecting infection in prosthetic joints
6. AASM encourages those student-athletes at risk for developing osa to visit a sleep clinic
7. Thailand: Partners Open Free AIDS Treatment Clinic in Renowned AIDS Temple in Lop Buri
8. MinuteClinic Becomes Participating Provider with Assurant Health
9. Therap Services Continues to Hire Experienced Developmental Disability Industry Clinicians for its Customer Support Team
10. Acupuncturists Relocation Tightens Relationship With Fertility Clinic
11. Cardiovascular Technologies to be Highlighted at 5th Annual Cleveland Clinic Medical Innovation Summit, Oct. 1-3
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 2Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 3Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 4Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 5Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 6Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 7Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 8Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 9Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 2Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 3Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 4Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 5ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 2ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 3ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 4ACCU CHEK 28R 29 Partners With MYLEstone Health to Enhance iPhone App Glucose Buddy and Web Site glucosebuddy com 61955 1ACCU CHEK 28R 29 Partners With MYLEstone Health to Enhance iPhone App Glucose Buddy and Web Site glucosebuddy com 61955 2ACCU CHEK 28R 29 Partners With MYLEstone Health to Enhance iPhone App Glucose Buddy and Web Site glucosebuddy com 61955 3Victory Pharma Inc Announces Launch of NAPRELAN 28R 29 Dose Card 61950 1Victory Pharma Inc Announces Launch of NAPRELAN 28R 29 Dose Card 61950 2Jubilant Organosys UAB and Southern Research Enter Into Drug Discovery Joint Venture 6469 1Jubilant Organosys UAB and Southern Research Enter Into Drug Discovery Joint Venture 6469 2Jubilant Organosys UAB and Southern Research Enter Into Drug Discovery Joint Venture 6469 3Jubilant Organosys UAB and Southern Research Enter Into Drug Discovery Joint Venture 6469 4